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ES-62 Protects Against Collagen-Induced Arthritis by
Resetting Interleukin-22 Toward Resolution of
Inflammation in the Joints
Miguel A. Pineda,1 David T. Rodgers,1 Lamyaa Al-Riyami,2 William Harnett,2 and
Margaret M. Harnett1
Objective. The parasitic worm–derived immuno-
modulator ES-62 protects against disease in the mouse
collagen-induced arthritis (CIA) model of rheumatoid
arthritis (RA) by suppressing pathogenic interleukin-17
(IL-17) responses. The Th17-associated cytokine IL-22
also appears to have a pathogenic role in autoimmune
arthritis, particularly in promoting proinflammatory
responses by synovial fibroblasts and osteoclastogen-
esis. The present study was undertaken to investigate
whether the protection against joint damage afforded by
ES-62 also reflects suppression of IL-22.
Methods. The role(s) of IL-22 was assessed by
investigating the effects of neutralizing anti–IL-22 anti-
bodies and recombinant IL-22 (rIL-22) on proinflam-
matory cytokine production, synovial fibroblast re-
sponses, and joint damage in mice with CIA in the
presence or absence of ES-62.
Results. Neutralization of IL-22 during the initi-
ation phase abrogated CIA, while administration of
rIL-22 enhanced synovial fibroblast responses and ex-
acerbated joint pathology. In contrast, after disease
onset anti–IL-22 did not suppress progression, whereas
administration of rIL-22 promoted resolution of inflam-
mation. Consistent with these late antiinflammatory
effects, the protection afforded by ES-62 was associated
with elevated levels of IL-22 in the serum and joints that
reflected a desensitization of the synovial fibroblast
responses. Moreover, neutralization of IL-22 during the
late effector stage of disease prevented ES-62–mediated
desensitization of synovial fibroblast responses and
protection against CIA.
Conclusion. IL-22 plays a dual role in CIA, being
pathogenic during the initiation phase while acting to
resolve inflammation and joint damage during estab-
lished disease. Harnessing of the tissue repair proper-
ties of IL-22 by ES-62 highlights the potential for
joint-targeted therapeutic modulation of synovial fibro-
blast responses and consequent protection against bone
damage in RA.
Rheumatoid arthritis (RA) is a chronic auto-
immune disorder characterized by synovial inflamma-
tion and resultant progressive joint damage. It has
become increasingly evident that IL-17–dependent re-
sponses play a central role in RA, with aberrant regula-
tion of Th17 cells being implicated in disease onset and
progression (1,2). In particular, IL-17 recruits neutro-
phils to the joint and induces secretion of proinflamma-
tory cytokines by synovial fibroblasts, resulting in the
promotion of osteoclastogenesis and hence, cartilage
and bone destruction (3). Elevated numbers of Th17
cells have been found in patients with RA (4,5), and a
pathogenic role of IL-17 in arthritis has been confirmed
in animal models (6,7). ES-62, a phosphorylcholine
(PC)–containing immunomodulator secreted by the fi-
larial nematode Acanthocheilonema viteae (8), protects
against collagen-induced arthritis (CIA) in mice (9,10)
by down-regulating IL-17 responses, via targeting of an
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inflammatory cellular network involving dendritic cells,
/ T cells, and Th17 cells (11).
Th17 cells also secrete IL-22, a cytokine generally
considered to be proinflammatory because of its coex-
pression with IL-17 during in vitro differentiation of
Th17 cells (12). However, there is increasing evidence
that IL-17 and IL-22 are differentially regulated and
often produced in vivo by different lymphocyte subsets.
Thus, transforming growth factor  is not required, and
IL-6 is sufficient, to induce IL-22 production by T cells
(13)—unlike the case for IL-17. However, the transcrip-
tion factor aryl hydrocarbon receptor is essential for the
production of IL-22 (14) by CCR10 “Th22” cells that
can be discriminated from Th17 cells (15). IL-22 is also
produced by innate lymphocytes (lymphoid tissue–
inducer cells, / T cells, and natural killer cells) (16),
but the widely expressed IL-22 receptor (IL-22R1–IL-
10R) is not usually expressed by hemopoietic cells (17).
Thus, IL-22 appears to provide a link between the
immune system and other tissues to promote their
innate immunity, in particular, to enhance antimicrobial
defense and tissue repair (17,18). Reflecting these pleio-
tropic effects, IL-22 has been reported to exhibit both
protective effects (hepatitis and inflammatory bowel
disease) and pathogenic effects (psoriasis) (13,19–21) in
inflammatory disease.
In the context of RA, mice that are deficient in
IL-22 are less susceptible to CIA and/or develop less
severe disease (22,23). Moreover, levels of IL-22 and
Th22 cells have been found to be elevated in the
periphery and synovia of RA patients (24–26), and IL-22
has been shown to induce proliferation of synovial
fibroblasts and promote RANKL production and osteo-
clastogenesis in vitro (27). We therefore investigated
whether the protective effects of ES-62 were also asso-
ciated with targeting of such IL-22 responses. Surpris-
ingly, these studies revealed that IL-22 can play dual
pathogenic and protective roles in CIA and that ES-62
harnesses the cytokine’s antiinflammatory effects on
synovial fibroblasts, to mediate its protection against
joint destruction. In describing a novel mechanism by
which a parasitic helminth–derived product acts to re-
duce autoimmune arthritis, these findings contribute to
our fundamental understanding of IL-22 immunobiol-
ogy and identify novel therapeutic targets in inflamma-
tory disease.
MATERIALS AND METHODS
Mice. Animals were maintained in the Biological Ser-
vices Units at the University of Glasgow and the University of
Strathclyde, in accordance with Home Office UK Licenses
PPL60/4300, PPL60/3791, PIL60/12183, PIL60/12950, and
PIL60/9576 and the respective ethics review boards of these
universities. CIA was induced in 8–10-week-old male DBA/1
mice (Harlan Olac) by intradermal immunization with bovine
type II collagen (MD Biosciences) in Freund’s complete
adjuvant (day 0) and by intraperitoneal (IP) administration in
phosphate buffered saline (PBS) (day 21). Purified endotoxin-
free ES-62 (2 g/dose) or PBS was administered subcutane-
ously on days 2, 0, and 21 (9), and cells were recovered from
draining lymph nodes (DLNs) and joints as previously de-
scribed (11). Mice were treated with endotoxin-free recombi-
nant IL-22 (rIL-22; ImmunoTools) (1 g/dose IP or 0.25
g/dose footpad injection, twice weekly as indicated) or
endotoxin-free mouse IgG (Europa Bioproducts) (100 g/dose
IP twice weekly beginning on day 7) or anti–IL-22 antibodies
(28) purified from the AM22.1 hybridoma (100 g/dose IP
twice weekly as indicated) (hybridoma kindly provided by Dr.
J. C. Renauld, Ludwig Institute for Cancer Research, Brussels,
Belgium). There were no significant differences in articular
scores between PBS-treated mice with CIA that were treated
with mouse IgG and those that were not treated with mouse
IgG. Mice were monitored for clinical symptoms of arthritis,
which were scored as 0 (normal), 1 (erythema), 2 (erythema
plus swelling), 3 (extension of swelling), or 4 (loss of function);
the overall disease score was the sum of the scores for each of
the 4 limbs. The date mice were removed from the study varied
slightly as euthanasia is required when a score of 10 is reached
or clinical symptoms develop in all 4 limbs. Other than dial
caliper (Kroeplin) analysis of paw thickness, all analyses were
also performed on the day the animal was removed from the
study.
Ex vivo analysis. DLN cells (106/ml) were incubated
with or without phorbol myristate acetate (PMA) (50 ng/ml)/
ionomycin (500 ng/ml) (Sigma-Aldrich) for 1 hour, followed by
addition of 10 g/ml brefeldin A (Sigma-Aldrich) for 5 hours
at 37°C with 5% CO2. Live cells were discriminated with
Live/Dead Fixable Aqua Dye (Invitrogen), and phenotypic
markers labeled using fluorescein isothiocyanate (FITC)–
conjugated anti-CD3 (BD PharMingen) and PerCP-
conjugated anti-CD4 or biotinylated anti-CD4 antibodies (de-
tected with Alexa Fluor 450–conjugated streptavidin) (BD
PharMingen) before the cells were fixed and permeabilized
according to protocols recommended by the supplier (BioLeg-
end). Cytokines were stained using phycoerythrin (PE)–Cy7–
conjugated anti–interferon- (anti-IFN), allophycocyanin-
conjugated or PerCP–Cy5.5–conjugated anti–IL-17A
(BioLegend), or PE-conjugated anti–IL-22 antibodies (R&D
Systems) for 30 minutes prior to analysis by flow cytometry,
with gating according to appropriate isotype controls. Detec-
tion of biologically relevant IL-22 cells was validated by in
vitro Th17/22 differentiation assays using 2 anti–IL-22 antibod-
ies (clone 140301 [R&D Systems] and clone 1H8PWSR [eBio-
science]) with or without rIL-22 pretreatment (10–40 g/ml);
essentially the same results were obtained with both clones
when dead cells were excluded from the analyses. Cells were
extracted from the joints of mice with CIA by collagenase
digestion and incubated with 10 g/ml brefeldin A for 5 hours
at 37°C. Following live cell discrimination with Live/Dead
Fixable Aqua Dye, cells were labeled with PerCP-conjugated
anti-Gr1 and FITC-conjugated anti-CD11b antibodies (eBio-
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science) before being fixed and permeabilized for staining for
IL-17, IL-22, and IFN expression.
Cytokine measurement. Levels of IL-17A, IL-22, and
IL-6 were determined by enzyme-linked immunosorbent assay,
according to the recommendations of the manufacturers (Bio-
Legend, R&D Systems, and eBioscience, respectively).
Synovial fibroblast explant cultures. Single-cell sus-
pensions recovered from all 4 limbs by collagenase digestion
(29) were pooled to avoid biasing results. Cells were cultured
for 12 hours in Dulbecco’s modified Eagle’s medium (Invitro-
gen) containing 2 mM glutamine, 50 units/ml penicillin, 50
g/ml streptomycin, and 10% fetal calf serum, after which
nonadherent cells were removed. Adherent cells were cultured
for 7 days and phenotyped using biotinylated anti-CD54,
PE–Cy7–conjugated anti-CD106, and PerCP-conjugated anti-
CD90.2 antibodies (eBioscience). Synovial fibroblasts were
stimulated in vitro with murine rIL-17 or rIL-22. After 24
hours, supernatants were collected for analysis.
Immunofluorescence. Preparation of tissue sections
(7 m), staining with hematoxylin and eosin, and detection of
IL-17 expression were performed as previously described (11).
To detect IL-22 expression, samples were stained for 12 hours
at 4°C with a rat anti-mouse IL-22 antibody (rat IgG isotype
control; R&D Systems) with DAPI counterstaining, followed
by detection using a biotinylated goat anti-rat IgG antibody
and Alexa Fluor 647–conjugated streptavidin. Images were
obtained using an LSM 510 Meta confocal laser coupled to an
Axiovert 200 microscope (Zeiss) and analyzed with Zeiss LSM
Image Browser software.
Statistical analysis. The significance of differences was
determined by Student’s unpaired 1-tailed t-test or by one-way
analysis of variance followed by Newman-Keuls post hoc test.
Articular scores were assessed by Mann-Whitney test. P values
less than 0.05 were considered significant.
RESULTS
Differential regulation of IL-17 and IL-22 re-
sponses by ES-62 in mice with CIA. Compared to the
PBS-treated group, the incidence of CIA was signifi-
cantly reduced in mice treated with ES-62, as were the
degree of hind paw swelling and clinical scores (even
among ES-62–treated animals that did develop CIA)
(Figure 1A). In parallel with the clinical findings, the
total number of DLN cells was significantly increased in
mice with CIA treated with PBS, but not in those
exposed to ES-62 in vivo, compared to the number in
naive mice without CIA (Figure 1B). However, while the
proportions of DLN cells and CD4 T cells that pro-
Figure 1. ES-62 differentially targets interleukin-17 (IL-17)– and IL-22–producing draining lymph node (DLN) cells in mice with collagen-induced
arthritis (CIA). A, Percent CIA incidence, mean  SEM paw width, and mean  SEM articular (clinical) score at various time points in a
representative experiment (n 7 phosphate buffered saline [PBS]–treated mice and 7 ES-62–treated mice) (first through third panels), and mean
SEM articular score (pooled from 6 independent experiments) at the time of removal from the experiment for all mice (fourth panel; n  38
PBS-treated mice and 36 ES-62–treated mice) and mice that had developed CIA (fifth panel; n  34 PBS-treated mice and 24 ES-62–treated mice).
B, Number of DLN cells in naive mice (n  9), PBS-treated mice with CIA (n  32), and ES-62–treated mice with CIA (n  25), and representative
plots of intracellular IL-22 and IL-17 expression from experiments using medium-treated or phorbol myristate acetate plus ionomycin
(PMA/iono)–stimulated DLN cells and CD4 T cells from PBS-treated mice with CIA. C and D, Percentages of DLN cells (C) or CD4 T cells
(D) expressing IL-17 or IL-22 in PBS-treated mice with CIA (n  32) and ES-62–treated mice with CIA (n  24). In B (left panel), C, and D, each
symbol represents an individual mouse; bars show the mean.   P  0.05 (versus ES-62 on the days indicated, in the second and third panels of
A);   P  0.01;   P  0.001.
1494 PINEDA ET AL
duced IL-17 in response to ex vivo stimulation with
either medium or PMA plus ionomycin were signifi-
cantly reduced by exposure to ES-62 in vivo, only the
levels of unstimulated IL-22–producing CD4 T cells
were significantly suppressed (Figures 1C and D). More-
over, whereas the ability of DLN and CD4 cells to
generate IL-17 ex vivo was significantly increased by
stimulation with PMA plus ionomycin (P  0.01 for
both), this was not the case with regard to production of
IL-22, as reflected by the finding that these cytokines
were generated by distinct subsets of DLN and CD4
cells (Figure 1B).
Although no differences could be detected at
early time points, in accordance with previous observa-
tions in human patients (30) and the proposed patho-
genic role of IL-22 in the CIA model (22,23), the mean
serum level of IL-22 was increased in PBS-treated mice
with CIA compared to naive controls at the last assess-
ment (Figure 2A). Rather unexpectedly, ES-62–treated
mice exhibited an even higher mean serum level of
IL-22. As this group segregated into high and low IL-22
producers, we investigated whether this was related to
disease progression and found that IL-22 levels (in both
PBS-treated and ES-62–treated mice) correlated in-
versely with CIA severity (Figure 2A). These findings
are in direct contrast to the association of serum IL-17
levels with articular score and their significant reduction
by in vivo exposure to ES-62 (11).
Analysis of joint-infiltrating cells revealed that
IL-17 and IL-22 were also produced predominantly by
distinct cell subsets within this population, although it
was not clear whether these included Th cells due to our
failure to detect expression of CD4 (presumably due to
its cleavage during the collagenase extraction proce-
dure). Nevertheless, a reduced proportion of the cells
expressed IL-17, and an increased proportion generated
IL-22, in the mice with CIA that had been exposed to
ES-62 in vivo (Figure 2B). Independent analysis of
individual mice showed that, whereas exposure to ES-62
resulted in significant suppression of the levels of IL-17–
and also IFN-producing cells, the levels of IL-22–
generating cells were maintained and even increased,
although this did not reach statistical significance (Fig-
ure 2C).
Onset of arthritis was detected in a few mice prior
to challenge with collagen. While exposure to ES-62
reduced the incidence of this (11%, versus 23% in
PBS-treated mice), it did not significantly ameliorate
pathology in the mice that developed disease. Perhaps
consistent with this, ES-62 did not suppress the (re-
Figure 2. ES-62–dependent up-regulation of IL-22 correlates with
protection against CIA. A, Serum IL-22 levels in naive mice (n  8),
PBS-treated mice with CIA (n  10), and ES-62–treated mice with
CIA (n  8), and inverse correlation (Pearson’s r  0.7298, P 
0.0006) between serum IL-22 levels and clinical scores in 18 PBS- or
ES-62–treated mice with CIA (each symbol represents the mean value
from triplicate analyses in an individual mouse). B, Representative
plots of intracellular IL-17 and IL-22 expression in pooled joint cells
from PBS-treated mice with CIA (n  4) and ES-62–treated mice with
CIA (n  4). C, Percentages of joint cells expressing IL-17,
interferon- (IFN), and IL-22 in PBS-treated mice with CIA (n 27,
17, and 24 for IL-17, IFN, and IL-22, respectively) and ES-62–treated
mice with CIA (n  20, 17, and 21, respectively). In A (left panel) and
C, each symbol represents an individual mouse; bars show the mean.
  P  0.05;   P  0.01;   P  0.001. See Figure 1 for other
definitions.
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duced) levels of IL-17–producing cells in the joints of
these mice. The differential IL-17:IL-22 ratios (0.49 and
0.21 in the PBS- and ES-62–treated groups, respectively,
postchallenge; 0.26 and 0.31, respectively, prechallenge)
and the ES-62 sensitivity observed in the 2 groups
further supported the idea that resetting of the IL-17/
Figure 3. ES-62 protection against CIA requires IL-22. A, Joint sections from representative PBS-treated mice with CIA, ES-62–treated mice with
CIA, and naive mice at weeks 2, 4, and 6 (articular scores 0, 4, and 8, respectively, at weeks 2, 4, and 6 in the PBS-treated mice and 0, 2, and 2,
respectively, in the ES-62–treated mice). Sections were stained with hematoxylin and eosin (H&E) or for IL-17 or IL-22 (red) or nuclei (DAPI; blue).
Isotype control sections were negative for IL-17 and IL-22. Joint structure is shown in the grayscale image. B  bone; AC  articular cavity; BM 
bone marrow. Original magnification  20 (1.9 zoom). B, Mean  SEM articular scores in mice with CIA treated with PBS (n  12), murine IgG
(100 g/dose; n  11), or anti–IL-22 (100 g/dose) twice weekly from day 7 (early IL-22; n  14) or from day 19 (late IL-22; n  4), or treated
intraperitoneally (IP) with PBS (n  7) or recombinant IL-22 ( rIL-22) (1 g/dose; n  7) twice weekly from day 7.   P  0.001. C, Mean 
SEM articular scores in mice with CIA treated with PBS plus IgG (n  13), ES-62 plus IgG (n  13), or ES-62 plus anti–IL-22 (n  12) and with
antibodies administered IP twice weekly from day 19 onward (100 g/dose) and ES-62 administered on days 2, 0, and 21 (2 g/dose), and percent
incidence of disease (score1) by treatment group.  P 0.05 (P values shown for specific days are versus treatment with ES-62 plus anti–IL-22).
See Figure 1 for other definitions.
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IL-22 balance in the joint correlates with ES-62–
mediated protection and perhaps suggests that
additional/alternative inflammatory parameters contrib-
uted to the pathogenesis in mice that developed arthritis
prior to challenge.
ES-62–mediated protection against CIA is de-
pendent on IL-22. In studies of the relationship of IL-17
and IL-22 expression with joint pathology in situ, we
have shown that, while expression of IL-17 was essen-
tially absent in the joints of naive mice, increasing levels
were observed throughout the progression of CIA and
correlated with induction of joint pathology (11). In the
present study we observed that in vivo exposure to ES-62
suppressed both the expression of IL-17 in the joints and
the development of joint disease (Figure 3A). In con-
trast, IL-22 was expressed in the joints of naive mice
predominantly in the bone area (not bone marrow), but
some IL-22 cells (10 m) could also be detected in
the synovium. Such IL-22 expression was also evident in
mice with CIA, but following an increase (within 2
weeks) during the disease initiation phase, it subse-
quently decreased over time. However, at 4 weeks some
IL-22 cells were found around the periphery of the
bone in mice with CIA, but not in naive or ES-62–
treated mice.
Exposure to ES-62 in vivo induced an inverse
pattern of expression, with the parasite product sup-
pressing the early peak of IL-22 expression (Figure 3A),
perhaps mirroring its inhibition of Th22 responses ob-
served in the DLNs, but inducing strong expression at
later time points consistent with its induction of IL-22
joint cells (peaking at week 4). These include synovium
cells (20 m; 20 digital magnification, 1.9 zoom) not
seen in PBS-treated mice with CIA. In terms of their
bipolar, spindle shape and prominent secretory machin-
ery (31) as evidenced by punctate IL-22 staining, these
cells are reminiscent of the IL-22–producing fibroblast-
like synoviocytes recently reported to be protective
against RA (32); hence, our results support the notion
that ES-62 mediates protection against joint pathology
via an IL-22–dependent mechanism.
To investigate the pathogenic role of IL-22, mice
were treated during the initiation phase (twice weekly
from day 7 of disease, as preliminary experiments estab-
lished that levels of IL-22–producing DLN cells were
elevated within 7–14 days) with either neutralizing anti–
IL-22 antibodies or rIL-22 to determine whether these
reagents could, respectively, block or promote develop-
ment of CIA (Figure 3B). Exposure to neutralizing
anti–IL-22 antibodies essentially abrogated develop-
ment of CIA, with no similar effect obtained with the use
of irrelevant IgG. Administration of rIL-22 tended to
promote both disease onset and increased severity (Fig-
ure 3B); indeed, the number of limbs affected in the
rIL-22–treated cohort necessitated termination of these
experiments before full pathology was established in the
PBS group. In contrast, when neutralizing anti–IL-22
antibodies were not administered until around the time
of onset of pathology but prior to challenge with colla-
gen (day 19), there was no significant disruption of the
development of CIA (Figure 3B), supporting the notion
that IL-22 has a pathogenic role during the early, but not
the later, phase of CIA.
As ES-62 acted to maintain and/or enhance IL-22
levels in serum, DLN cells, and joints during established
disease (within 3–4 weeks), we also investigated whether
administration of neutralizing anti–IL-22 antibodies
around the time of onset of joint pathology (day 19)
would abrogate the protective effects of ES-62. The
results of these experiments (Figure 3C) indicated that
the protective effects of ES-62 were indeed dependent
on IL-22.
ES-62 and IL-22 down-regulate synovial fibro-
blast responses and suppress joint inflammation. To
investigate the mechanisms involved in the observed
protection against CIA, we examined the effects of
IL-17, IL-22, and ES-62 on joint inflammation. Consis-
tent with the suppression of pathogenic IL-17 responses,
the total number of infiltrating cells, and in particular,
CD11bGr1 neutrophils (Figure 4A), was signifi-
cantly higher in the joints of mice with CIA treated with
PBS relative to those exposed to ES-62. Moreover,
infiltrating cells from the ES-62–treated mice showed
significantly reduced levels of IL-6 release (Figure 4A).
Most of the neutrophils (70%) isolated from
the joints of animals with CIA were able to produce
IFN (Figure 4B), and while this proportion was not
altered by exposure to ES-62 (Figure 4C), their lower
numbers would contribute to the observed reduction of
IFN-producing cells in the joint (Figure 2C). Some of
the neutrophils appeared to express IL-22 (Figure 4B),
and the proportion of IL-22Gr1CD11b cells and
their levels of IL-22 expression tended to be increased by
ES-62 (Figure 4C), although neither increase reached
statistical significance. Nevertheless, such immuno-
modulation results in a shift in the balance of cytokines,
with a relative reduction of IL-6/IL-17/IFN expression
and increase in IL-22 expression (Figures 2C, 4A, and
4C). Consistent with the ES-62–mediated promotion of
IL-22 levels, there was a negative correlation between
the proportion of this IL-22Gr1CD11b subset of
neutrophils and the severity of disease (Figure 4D),
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suggesting that ES-62 promotes induction of an IL-22
neutrophil subset that infiltrates the joint to mediate
protection against CIA.
As hemopoietic cells generally do not express
IL-22R, we next investigated whether the IL-22–
dependent protective effects of ES-62 reflected modu-
lation of the function of synovial fibroblasts, which not
only secrete cytokines (such as IL-6) that recruit inflam-
matory cells (such as neutrophils) to the joint, but also
act to directly mediate joint destruction by releasing
proteolytic enzymes (matrix metalloproteinases) that
degrade cartilage and by secreting factors (e.g.,
RANKL) that further contribute to bone destruction by
activating osteoclastogenesis and promoting bone re-
sorption (33–35). Consistent with this proposal, when
explant cultures of synovial fibroblasts (CD90.2
CD54CD106) (Figure 5A) extracted from mice with
CIA were incubated with rIL-22 the production of IL-6,
rather than being stimulated, was inhibited to below
basal levels (Figure 5B), in direct contrast with the
Figure 4. ES-62 modulates cellular infiltration of the joints of mice with CIA. A, Numbers of infiltrating cells in the joints of PBS-treated mice with
CIA (n  28) and ES-62–treated mice with CIA (n  22), numbers of CD11bGr1 cells in the joints of PBS-treated mice with CIA (n  22) and
ES-62–treated mice with CIA (n  17), and production of IL-6, determined by enzyme-linked immunosorbent assay, in joint cells (106/ml) from
PBS-treated mice with CIA (n  11), ES-62–treated mice with CIA (n  12), and naive mice (n  3) (each symbol represents the mean value from
triplicate analyses in an individual mouse). B, Gating strategy for analysis of Gr1CD11b cells isolated from the joints of PBS-treated mice with
CIA, and their expression of IL-22 and interferon- (IFN). C, Percentages of IFN and IL-22 CD11bGr1 joint cells, and mean fluorescence
intensity (MFI) of IL-22 expression by CD11bGr1 joint cells from PBS-treated mice with CIA (n  17 and 13 for IFN and IL-22, respectively)
and ES-62–treated mice with CIA (n  17 and 13, respectively). D, Inverse correlation (Pearson’s r  0.86, P  0.0075) between the percentage
of IL-22CD11bGr1 cells and clinical scores in mice with CIA. (The same trend was found in 2 additional independent experiments.) In A and
C, each symbol represents an individual mouse; bars show the mean.   P  0.05. See Figure 1 for other definitions.
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results obtained with rIL-17 incubation. Moreover, ex-
plant cultures of synovial fibroblasts from mice with CIA
exposed to ES-62 showed significantly reduced basal
production of IL-6 and were less responsive to rIL-17
and rIL-22 than fibroblast cultures from PBS-treated
mice (Figure 5C). Indeed, even though culture of syno-
vial fibroblasts with IL-22 in vitro suppressed their basal
release of IL-6, the production of this cytokine by cells
from ES-62–treated mice was still lower than that by
cells from PBS-treated mice with CIA. Collectively,
these data indicate that ES-62 may act via IL-22 to
suppress synovial fibroblast–mediated inflammation of
the joints during established disease.
To directly investigate the potential dual roles of
IL-22 in joint inflammation, mice with CIA were admin-
istered rIL-22 in the right footpads (PBS in the left
footpads) twice weekly from day 7 in order to mimic
local up-regulation of IL-22 during both the initiation
and the effector phases of disease (Figure 6). Treatment
with rIL-22 initially increased the articular score (peak
on day 25) before beginning to mediate some resolution
of joint inflammation, resulting in suppression of the
articular score relative to that in untreated mice with
CIA by the end of the experimental period. These
protective effects were more pronounced when rIL-22
was first administered to the footpads around the time of
disease onset (twice weekly from day 19) to mimic the
elevated levels observed in mice with established CIA
that had been exposed to ES-62 in vivo. With this
protocol there was significant reduction in pathology
(Figure 6A). Although the inflammation in the footpads
that received this “therapeutic” administration of rIL-22
was also reduced relative to that in PBS-treated footpads
of the same animals, it was evident that the pattern of
IL-22 first promoting and then resolving joint inflamma-
tion was paralleled, albeit to a lesser extent and follow-
ing a slight delay, in the PBS-treated joints. This suggests
that the effects of rIL-22 were being transferred to these
limbs, presumably via systemic effects of the injected
rIL-22 or perhaps by its functional suppression of
“pathogenic” fibroblasts, which has been reported to
mediate clinical spreading of arthritis between joints
(35).
Finally, to confirm that these pathogenic and
protective effects of rIL-22 were targeting synovial fibro-
blasts in the joint, we analyzed IL-6 production by
synovial fibroblast explant cultures from paws treated
with rIL-22 and from PBS-treated control paws of the
same animals. In accordance with their pathogenic sta-
tus (35), synovial fibroblasts from mice with CIA exhib-
ited enhanced IL-6 production relative to those from
naive mice (Figure 6B), and administration of rIL-22 to
the paw from the time of the initiation phase of CIA
resulted in even higher production of IL-6 by synovial
fibroblasts. In contrast, when rIL-22 administration did
not begin until around the time of onset of joint pathol-
ogy, the capacity to produce IL-6 tended to be reduced
toward the levels observed in naive mice (Figure 6B).
Importantly, while synovial fibroblasts from ES-62–
treated mice exhibited reduced IL-6 responses relative
to those from mice treated with PBS (Figure 5C) or PBS
plus IgG (Figure 6C), such desensitization was partially
overcome in synovial fibroblasts derived from mice with
CIA that were exposed to both ES-62 and neutralizing
anti–IL-22 antibodies in vivo (Figure 6C), corroborating
Figure 5. ES-62 desensitizes IL-17–mediated production of IL-6 by
synovial fibroblasts. A, CD90.2, CD54, and CD106 expression (black
lines) by synovial fibroblasts from mice with CIA (gray lines represent
isotype controls). Fibroblasts were cultured ex vivo for 7 days prior to
in vitro stimulation. B, IL-6 production by synovial fibroblasts from
PBS-treated mice with CIA, in response to recombinant IL-17 (rIL-17)
or rIL-22 (10 ng/ml). Three independent cultures of cells obtained by
pooling mice (n  7) within each group were performed. Values are
the mean  SEM (calculated using the mean result from the triplicate
experiments). C, IL-6 production over 24 hours by synovial fibroblast
explant cultures (106/ml) from individual PBS-treated mice with CIA
or ES-62–treated mice with CIA, in response to fresh medium, rIL-17
(10 ng/ml), or rIL-22 (10 ng/ml). For PBS-treated mice, n 12, 11, and
12 for fresh medium, rIL-17, and rIL-22, respectively; for ES-62–
treated mice, n  14, 13, and 14, respectively. Each symbol represents
the mean value from triplicate determinations (by enzyme-linked
immunosorbent assay) in an individual mouse; bars show the mean.
  P  0.05;   P  0.001. See Figure 1 for other definitions.
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the antiinflammatory role of IL-22 in ES-62–mediated
protection against joint inflammation.
DISCUSSION
ES-62 protects against CIA by targeting priming
of a complex IL-17–producing cellular network that
involves dendritic cells and / and CD4 T cells, and
also by acting directly on Th17 cells (11). In this study,
we investigated whether ES-62–mediated suppression of
IL-22 responses also contributed to its protective effects
in CIA, as this Th17-associated cytokine has similarly
been implicated in CIA pathogenesis (22,23). Although
we confirmed the pathogenic role of IL-22 in the initi-
ation phase of CIA, we found, surprisingly, that ES-62
treatment appeared to enhance IL-22 responses follow-
ing onset of disease. Moreover, during established dis-
ease, serum levels of IL-22 correlated inversely with
articular scores, and local administration of IL-22 re-
duced joint inflammation. Furthermore, ES-62–
mediated protection against CIA could be blocked by
administration of neutralizing anti–IL-22 antibodies
(from day 19). Collectively, these data suggest that IL-22
has dual pro- and antiinflammatory roles in CIA, with
early, systemic IL-17 and IL-22 (Th22) responses coop-
erating to drive pathogenesis, while later, IL-22 acts at
the site of inflammation to counterregulate IL-17 pro-
inflammatory signaling and promote resolution of joint
disease.
Figure 6. Recombinant IL-22 (rIL-22) modulates synovial fibroblast responses to IL-17. A, Mice with CIA were injected twice weekly with rIL-22
(0.25 g/dose) in the right footpad or PBS (50 l) in the left footpad (injection controls). Mice receiving no additional treatment were used as disease
controls. IL-22 injections were begun at the initiation phase of CIA (day 7 [early]) (n  8) or around the time of onset of joint pathology (day 19
[late]) (n 7). Values are the mean SEM (calculated using the mean clinical score of the 2 paws undergoing the same treatment in each individual
mouse). B and C, Paws from individual mice with CIA receiving the indicated treatments, naive mice, and disease control mice with CIA were pooled
to generate synovial fibroblast explant cultures representing the various treatment groups. Release of IL-6 after 24 hours of treatment with medium
alone (C) or with IL-17 (B) was evaluated by enzyme-linked immunosorbent assay. Values are the mean  SEM (calculated using the mean of
triplicate determinations of IL-6 values from 3 independent cultures of cells from each treatment group).   P  0.05;   P  0.01;   P 
0.001 (P value shown for day 25 in the middle panel of A is versus untreated mice with CIA). See Figure 1 for other definitions.
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IL-22 is involved in the host response to infec-
tious diseases by promoting inflammation (36,37) but,
reflecting its tissue repair properties, it exerts both pro-
and antiinflammatory actions in allergic and auto-
immune inflammatory disorders (13,19,20,38–40). In-
deed, our results demonstrating dual pathogenic and
inflammation-resolving roles of IL-22 are reminiscent of
the findings in studies using models of ovalbumin-
induced airway hyperresponsiveness, in which IL-22
appears to be essential for antigen sensitization (41) yet
acts to resolve established airway inflammation. Like-
wise, in asthma patients, while serum IL-22 levels are
elevated and correlate positively with disease severity
(41,42), levels in bronchoalveolar lavage fluid correlate
inversely with those of proinflammatory chemokines,
and IL-22 can inhibit the release of proinflammatory
mediators by human bronchial epithelial cells (39).
Results of other recent studies have called into question
the idea that IL-22 has a solely pathogenic role in
arthritis, as antigen (methylated bovine serum albumin
[BSA])–induced, IL-17–mediated joint inflammation
was found to occur independent of IL-22 (43) and
systemic administration of rIL-22 was protective in late
stages of disease in the CIA model (44). Further sup-
porting the notion of an inflammation-resolving role of
this cytokine, IL-22 has recently been shown to poten-
tially modulate the IL-23/IL-17 inflammatory axis in RA
patients by down-regulating IL-23 and IL-17RC expres-
sion in fibroblast-like synoviocytes (32).
Although full understanding of the mechanisms
underlying the IL-22–driven resolution of articular in-
flammation requires further investigation, the above
findings are consistent with the notion that ES-62 resets
the balance of IL-22/IL-17 signaling in the inflamed
synovium from proinflammatory toward desensitization
of “pathogenic” synovial fibroblast responses, conse-
quently reducing infiltration of effector cells and joint
damage. Thus, and consistent with reports that IL-22
promotes osteoclast differentiation from human mono-
cytes via RANKL production by synovial fibroblasts in
vitro (27), administration of rIL-22 to the paws during
the initiation phase of CIA resulted in enhanced basal
and IL-17–stimulated IL-6 responses by synovial fibro-
blasts. In contrast, exposure to IL-22 in vitro was found
to suppress the levels of IL-6 secreted by synovial
fibroblasts derived from mice with established CIA,
while synovial fibroblasts from ES-62–treated mice with
CIA, which exhibited elevated serum and joint levels of
IL-22 following disease onset, demonstrated desensi-
tized basal and IL-17–stimulated IL-6 responses. These
latter data are consistent with reports that Th17 cells
from IL-22–deficient mice induced synovial cells to
produce higher levels of IL-6 than those from wild-type
mice (23), suggesting that (aberrant) release of this
proinflammatory cytokine may normally be limited by
IL-22. Our finding that neutralizing anti–IL-22 anti-
bodies could prevent both ES-62–mediated desensitiza-
tion of synovial fibroblast responses and protection
against CIA strongly suggests that IL-22 has a role in
desensitizing synovial fibroblasts and promoting resolu-
tion of joint inflammation in established arthritis.
A key question therefore relates to the trigger
that switches IL-22 from a pro- to an antiinflammatory
cytokine in CIA. Our data suggest that this occurs
around the time of onset of joint pathology (days 20–25)
as in the early stages, both systemically and locally in the
joint, IL-17 and IL-22 (in the relatively low levels at
which they are present) appear to act cooperatively (and
may indeed both be derived from Th17 cells as described
for IL-1–driven arthritis [45]) to promote pathogenesis,
whereas in the IL-22–mediated protection phase, IL-17
levels are high and IL-17 and IL-22 appear to be
produced by antagonistic cell populations. It is not clear
what are the major cell producers of “antiinflammatory
IL-22” or their precise targets other than synovial fibro-
blasts; elucidation of this may help explain the failure of
neutralizing anti–IL-22 antibodies to exacerbate disease
when administered systemically following the onset of
pathology. Moreover, in addition to reducing the levels
of neutrophils infiltrating the joints, it appears that
ES-62 may have modified such cells functionally to a
“protective IL-22–producing phenotype,” perhaps sug-
gesting that the parasite product provides additional
signals to rewire cells to become “protective” sources of
IL-22 and/or targets of the antiinflammatory action of
IL-22.
It is therefore of interest that infection with the
helminth Trichuris trichiura has been reported to thera-
peutically alleviate ulcerative colitis (46) by a mechanism
that is dependent on expansion of IL-22–positive cells.
This suggests that induction of the tissue repair proper-
ties of IL-22 could be a mechanism evolved by worms to
promote healing of wounds arising from their invasion,
to prevent harmful pathology to the host and/or inflam-
matory responses that could result in their expulsion.
Exploiting the ability of helminth products such as ES-62
to induce such inflammation- and wound-resolving re-
sponses to treat autoimmune disorders is therefore an
attractive prospect. Toward this end, we have obtained
preliminary data suggesting that PC (the active moiety
of ES-62), when conjugated to BSA, also significantly
promotes generation of joint inflammation–resolving
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IL-22. Indeed, studies of PC–BSA were the starting
point for our development of drug-like derivatives that
mimic the ability of ES-62 to suppress CIA by targeting
pathogenic IL-17 responses (47) and provide proof-of-
concept that exploiting the actions of helminth-derived
immunomodulators may potentially open novel avenues
for drug discovery in RA.
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